Simcere Given OK by SFDA for Flu Drug Relenza
February 11, 2010 at 00:35 AM EST
Simcere Pharma (先声药业) reported it has received SFDA approval to manufacture and market Relenza (zanamivir), the flu treatment developed by GlaxoSmithKline (NYSE: GSK). Relenza, an inhaled neuraminidase inhibitor, is one of only two approved drugs for treating H1N1 flu. Simcere holds an exclusive license for Relenza in China. More details... Stock Symbol: (NYSE: SCR)